Klivira
Request demo

Streamlining Medicare Ocrevus Prior Authorization Workflows

Optimizing the Medicare Ocrevus prior authorization process is critical for ensuring timely patient access to this essential therapy. Klivira provides a robust platform to manage these complex workflows efficiently.

For revenue cycle directors and prior authorization coordinators, navigating the specific requirements for high-cost, specialty drugs like Ocrevus under Medicare can be challenging. The fragmented nature of Original Medicare PA, coupled with varied Medicare Advantage plan rules, demands precise operational strategies to minimize delays and denials. Our solution is designed to bring clarity and automation to these critical processes.

Ocrevus: A High-Volume Prior Authorization Target

Ocrevus (ocrelizumab) is a monoclonal antibody therapy indicated for relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). As a high-cost, specialty infusion administered in an outpatient setting, Ocrevus frequently requires prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans. Its therapeutic significance makes efficient PA crucial for patient care continuity.

Understanding Medicare Prior Authorization for Ocrevus

Medicare's prior authorization landscape is bifurcated. Original Medicare (Parts A and B) has a limited scope for PA, primarily for specific services like certain outpatient department services, DME, or ambulance transport. For Ocrevus, typically covered under Medicare Part B as a medical benefit, PA requirements are determined by the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction, aligning with National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs). Medicare Advantage (MA) plans, operated by private insurers, generally have broader PA requirements, often mirroring commercial plan policies and formularies.

Key Submission Channels for Medicare Ocrevus Prior Authorization

  • **Original Medicare (Part B)**: Submissions route through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction. Klivira's MAC-aware routing handles per-jurisdiction specifics for MACs such as Noridian, NGS, WPS, Palmetto, FCSO, and Novitas.
  • **Medicare Advantage (MA) Plans**: PA for Ocrevus under MA plans follows the specific requirements of the private plan, often involving direct portal submissions or electronic PA (ePA) channels.
  • **Medicare Part D (Pharmacy Benefit)**: While Ocrevus is typically a Part B medical benefit, Part D plans administer pharmacy PA for other drugs per CMS-approved formularies and step-therapy protocols. Klivira supports NCPDP SCRIPT for Part D PA where applicable.

Policy Adherence: NCDs, LCDs, and Documentation for Ocrevus

For Original Medicare, coverage criteria for Ocrevus are primarily governed by CMS-published National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) issued by the MACs. These policies outline medical necessity, diagnostic criteria, and treatment protocols. Accurate documentation, including specific NCD/LCD citations, MAC jurisdiction, and effective dates, is paramount for successful prior authorization. Klivira integrates policy logic to align submissions with these critical requirements.

Klivira's Role in Automating Ocrevus PA for Medicare

Klivira streamlines the Medicare Ocrevus prior authorization process by automating data extraction from EMRs, intelligent routing to the correct MAC or MA plan portal, and real-time status tracking. Our platform reduces manual effort, minimizes errors, and helps accelerate approval times by ensuring submissions are complete and compliant with specific NCDs and LCDs. This targeted automation is crucial for high-volume specialty drugs where any delay impacts patient care and revenue cycles.

Frequently asked questions

Does Original Medicare always require prior authorization for Ocrevus?

Original Medicare has a limited scope for prior authorization. While Ocrevus is typically a Part B drug, PA requirements for specific outpatient services, including infusions, are determined by your regional Medicare Administrative Contractor (MAC) based on applicable National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs). It's essential to verify current requirements with your MAC.

How do Medicare Advantage plans handle Ocrevus prior authorization differently?

Medicare Advantage (MA) plans are private health plans that contract with CMS. Unlike Original Medicare, MA plans generally have broader prior authorization requirements, which can vary significantly by plan. These plans often have their own formularies, step-therapy protocols, and specific submission channels that must be adhered to for Ocrevus coverage.

What documentation is typically needed for Ocrevus prior authorization under Medicare?

Common documentation includes patient demographics, clinical notes supporting the diagnosis of RMS or PPMS, physician's orders for Ocrevus, infusion records, and evidence of previous treatments or contraindications to alternative therapies. For Original Medicare, specific references to relevant NCDs or LCDs are often required to demonstrate medical necessity.

Can Klivira integrate with my EMR to automate Ocrevus PA for Medicare patients?

Yes, Klivira is designed for seamless integration with major EMR systems using standards like SMART on FHIR. This allows for automated extraction of necessary clinical data directly from the patient record, significantly reducing manual data entry and improving accuracy for Medicare Ocrevus prior authorization submissions.

How does Klivira ensure compliance with MAC-specific rules for Ocrevus PA?

Klivira's platform incorporates MAC-aware routing and policy logic. This means it can identify the correct MAC for your jurisdiction (e.g., Noridian, NGS, Novitas) and apply the specific NCDs and LCDs relevant to Ocrevus. This ensures that submissions are tailored to each MAC's requirements, enhancing the likelihood of approval.

Related coverage

Other ocrevus prior authorization by payer

Other ocrevus prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo